bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
196 hedge funds and large institutions have $997M invested in bluebird bio in 2021 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 63 increasing their positions, 61 reducing their positions, and 59 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 61
0.11% less ownership
Funds ownership: 6.08% → 5.97% (-0.11%)
16% less funds holding
Funds holding: 232 → 196 (-36)
41% less capital invested
Capital invested by funds: $1.7B → $997M (-$703M)
42% less call options, than puts
Call options by funds: $10.4M | Put options by funds: $17.8M
56% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 59
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$50.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$38.2M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$17.7M |
| 4 |
AC
Armistice Capital
New York
|
+$14M |
| 5 |
SC
Sessa Capital
New York
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$40.1M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$37M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18M |
| 4 |
DM
Deerfield Management
New York
|
-$15.4M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$13.9M |
BLUE Hedge Fund Activity: Q3 2021 in Review
196 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2021, worth a combined $997M — down 41% from $1.7B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of BLUE and 26 opened new positions — a net loss of 33 holders — while 61 trimmed existing stakes and 63 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $50.2M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $40.1M sold.
- 196 institutional investors held bluebird bio (BLUE) as of Q3 2021, down from 232 in Q2 2021.
- Funds reported $997M of bluebird bio stock for Q3 2021, down 41% quarter-over-quarter.
- 26 funds opened new bluebird bio positions in Q3 2021 and 59 closed out, a net change of -33 holders.
- The largest bluebird bio buyer in Q3 2021 was Baker Bros. Advisors, an estimated $50.2M added.
- The largest bluebird bio seller in Q3 2021 was Suvretta Capital Management, an estimated $40.1M sold.
Based on aggregated 13F filings for Q3 2021.